The management of patients with low ovarian reserve is one of the most important challenges in every day practice in the infertility clinic. Different treatment options for low ovarian reserve are androgenization, aromatase inhibitor—letrozole, dehydroepiandrosterone, transdermal testosterone, and growth hormone. The use of androgenization approaches with letrozol, DHEA, and transdermal testosterone lack of robust data showing an improvement in live birth rates in women with poor ovarian response. Data for the use of transdermal testosterone in a recent meta-analysis showed an increase in live birth rate. The use of growth hormone is conditioned by the cost of this alternative, but a review showed a more favourable result in live birth rate.